Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $6,353 | 3 | 94.9% |
| Food and Beverage | $190.03 | 7 | 2.8% |
| Honoraria | $150.00 | 1 | 2.2% |
| Education | $1.10 | 1 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GlaxoSmithKline, LLC. | $3,900 | 2 | $0 (2023) |
| Merck Sharp & Dohme LLC | $2,453 | 1 | $0 (2023) |
| Alexion Pharmaceuticals, Inc. | $182.36 | 2 | $0 (2024) |
| Alnylam Pharmaceuticals Inc. | $54.57 | 2 | $0 (2024) |
| UPSHER-SMITH LABORATORIES LLC | $28.59 | 1 | $0 (2024) |
| Novo Nordisk Inc | $28.17 | 1 | $0 (2024) |
| GENZYME CORPORATION | $24.12 | 1 | $0 (2020) |
| Novartis Pharmaceuticals Corporation | $22.22 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $140.91 | 5 | Alexion Pharmaceuticals, Inc. ($32.36) |
| 2023 | $6,378 | 4 | GlaxoSmithKline, LLC. ($3,900) |
| 2022 | $1.10 | 1 | Travere Therapeutics, Inc. ($1.10) |
| 2020 | $24.12 | 1 | GENZYME CORPORATION ($24.12) |
| 2019 | $150.00 | 1 | Alexion Pharmaceuticals, Inc. ($150.00) |
All Payment Transactions
12 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/05/2024 | Novo Nordisk Inc | Rivfloza (Drug) | Food and Beverage | In-kind items and services | $28.17 | General |
| Category: Rare Disease | ||||||
| 11/19/2024 | UPSHER-SMITH LABORATORIES LLC | TORPENZ (Drug), VIGADRONE | Food and Beverage | In-kind items and services | $28.59 | General |
| Category: NEUROLOGY | ||||||
| 11/07/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $22.22 | General |
| 08/27/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $32.36 | General |
| Category: Rare Disease | ||||||
| 04/11/2024 | Alnylam Pharmaceuticals Inc. | OXLUMO (Drug) | Food and Beverage | In-kind items and services | $29.57 | General |
| Category: Genetic Disease | ||||||
| 07/05/2023 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $1,950.00 | General |
| 07/05/2023 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $1,950.00 | General |
| 06/01/2023 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $2,452.50 | General |
| Category: CARDIOVASCULAR | ||||||
| 04/22/2023 | Alnylam Pharmaceuticals Inc. | OXLUMO (Drug) | Food and Beverage | In-kind items and services | $25.00 | General |
| Category: Genetic Disease | ||||||
| 10/13/2022 | Travere Therapeutics, Inc. | Thiola (Drug) | Education | In-kind items and services | $1.10 | General |
| Category: Kidney Stones | ||||||
| 02/26/2020 | GENZYME CORPORATION | THYMOGLOBULIN (Biological) | Food and Beverage | In-kind items and services | $24.12 | General |
| Category: Oncology | ||||||
| 06/27/2019 | Alexion Pharmaceuticals, Inc. | Soliris (Drug) | Honoraria | Cash or cash equivalent | $150.00 | General |
| Category: Immunology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2021 | 1 | 12 | 30 | $28,800 | $4,222 |
| 2020 | 1 | 18 | 29 | $18,560 | $3,324 |
All Medicare Procedures & Services
2 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 12 | 30 | $28,800 | $4,222 | 14.7% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 18 | 29 | $18,560 | $3,324 | 17.9% |
About Dr. Patricia Weng, M.D
Dr. Patricia Weng, M.D is a Pediatric Nephrology healthcare provider based in Los Angeles, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/02/2007. The National Provider Identifier (NPI) number assigned to this provider is 1730301656.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Patricia Weng, M.D has received a total of $6,694 in payments from pharmaceutical and medical device companies, with $140.91 received in 2024. These payments were reported across 12 transactions from 9 companies. The most common payment nature is "Consulting Fee" ($6,353).
As a Medicare-enrolled provider, Weng has provided services to 30 Medicare beneficiaries, totaling 59 services with total Medicare billing of $7,546. Data is available for 2 years (2020–2021), covering 2 distinct procedure/service records.
Practice Information
- Specialty Pediatric Nephrology
- Location Los Angeles, CA
- Active Since 05/02/2007
- Last Updated 11/21/2013
- Taxonomy Code 2080P0210X
- Entity Type Individual
- NPI Number 1730301656
Products in Payments
- Soliris (Drug) $150.00
- OXLUMO (Drug) $54.57
- ULTOMIRIS (Biological) $32.36
- TORPENZ (Drug) $28.59
- Rivfloza (Drug) $28.17
- THYMOGLOBULIN (Biological) $24.12
- Thiola (Drug) $1.10
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pediatric Nephrology Doctors in Los Angeles
Isidro Salusky, M.d, M.D
Pediatric Nephrology — Payments: $65,969
Dr. Ora Yadin, M.d, M.D
Pediatric Nephrology — Payments: $47,828
Dr. Elaine Kamil, M.d, M.D
Pediatric Nephrology — Payments: $15,840
Dr. Mark Hanudel, Md, MD
Pediatric Nephrology — Payments: $15,633
Dr. Robert Ettenger, M.d, M.D
Pediatric Nephrology — Payments: $6,981
Rachana Srivastava
Pediatric Nephrology — Payments: $305.73